Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells

• Published in: Gynecologic oncology Vol. 98; no. 1; pp. 45 - 53
• Main Authors: Lee, Keun-Ho, Yim, Eun-Kyoung, Kim, Chan-Joo, Namkoong, Sung-Eun, Um, Soo-Jong, Park, Jong-Sup
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2005
• Subjects: Antineoplastic Agents, Phytogenic - pharmacology; Cell Cycle - drug effects; Cell Cycle - genetics; Cell Cycle Proteins - analysis; Cell Cycle Proteins - biosynthesis; Cell Cycle Proteins - genetics; Cervical carcinoma; Electrophoresis, Gel, Two-Dimensional; Female; HeLa Cells; HPV; Humans; Mitotic checkpoint protein BUB3; Paclitaxel; Paclitaxel - pharmacology; Poly-ADP-Ribose Binding Proteins; Proteomics; RNA, Small Interfering - genetics; Small interfering RNA (siRNA); Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods; Tetrazolium Salts; Thiazoles; Transfection; Uterine Cervical Neoplasms - drug therapy; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - metabolism; Uterine Cervical Neoplasms - pathology; Small interfering RNA (siRNA); Cervical carcinoma; Paclitaxel; Proteomics; HPV; Mitotic checkpoint protein BUB3

Paclitaxel (Taxol®), a potent drug of natural origin isolated from the bark of the Pacific yew, is widely used in the treatment of ovarian, lung and breast cancer. At present, there is little information regarding the anti-cancer mechanism of paclitaxel against cervical carcinoma cells. We thus trie...